Given these data and towards improving MPS VI patient vision, it was hypothesized that a similar approach fixing the variables of vector dose, genome context (promoter, poly(A), and single-stranded transgene), capsid, and administered volume, while substituting IDUA with ARSB cDNA, would reverse corneal clouding in an MPS VI model. The gene discussed is ARSB; the disease is mucopolysaccharidosis type 6.